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The calcimimetic AMG 073 reduces parathyroid hormone and Secondary hyperparathyroidism is characterized by
calcium x phosphorus in secondary hyperparathyroidism. parathyroid gland hyperplasia and increased concentra-
Background. A need exists for a therapy that lowers para- tions of parathyroid hormone (PTH) [1, 2]. Elevated PTH
thyroid hormone (PTH) without increasing calcium x phospho-
levels may adversely affect a variety of organs, includingrus in patients with secondary hyperparathyroidism. The calci-
the central nervous system, cardiac and pulmonary func-mimetic AMG 073 increases the sensitivity of the parathyroid
tion [3–5]. Furthermore, Block et al found that elevatedcalcium-sensing receptor to extracellular calcium, thereby re-
ducing PTH secretion. Consequently, AMG 073 may provide PTH levels are associated with an increase in the relative
a novel therapy for secondary hyperparathyroidism. risk of mortality [6]. Abnormalities of bone and mineral
Methods. Seventy-eight hemodialysis patients with second- metabolism are another important complication in these
ary hyperparathyroidism were enrolled into this 18-week, dou-
patients. Bone histology in these patients often revealsble-blind, randomized, placebo-controlled, dose titration study.
the pathology of osteitis fibrosa cystica [7, 8].Daily oral AMG 073 doses were administered to determine
Current strategies for managing secondary hyperpara-the effect on PTH, serum calcium, phosphorus, and calcium x
phosphorus. thyroidism in patients with end-stage renal disease (ESRD)
Results. The mean baseline PTH was similar in patients ad- utilize large oral doses of calcium or noncalcium-con-
ministered AMG 073 or placebo (632 280.1 pg/mL vs. 637 taining phosphate-binding agents to control hyperphos-
455.9 pg/mL, respectively). PTH decreased by 26.0% in the
phatemia while the vitamin D sterols, calcitriol, paricalci-AMG 073-treated group, compared with an increase of 22.0%
tol or doxercalciferol, are administered to lower PTHin the placebo group (P  0.001). A greater proportion in
levels [9–12]. Unfortunately, episodes of hypercalcemiathe AMG 073 group (38%) had a decrease in PTH 30%,
compared with the placebo group (8%) (P 0.001). Decreases are common in patients treated with calcium-containing
in PTH were independent of baseline vitamin D usage. Patients phosphate-binding agents and serum calcium and phos-
receiving AMG 073 had an 11.9% decrease in calcium x phos- phorus levels often rise after the administration of su-
phorus compared with a 10.9% increase in the placebo group praphysiological doses of vitamin D [13–15]. Both ther-(P  0.001). Use of vitamin D sterols, as well as both calcium
apeutic interventions may contribute to vascular andand noncalcium-containing phosphate binders. were similar
soft-tissue calcification [16]. Moreover, neither treatmentbetween treatment groups. Administration of AMG 073 was
safe and well tolerated in this 18-week study. immediately decreases PTH synthesis and secretion.
Conclusions. The calcimimetic AMG 073 decreases both Consequently, an unmet medical need exists for a ther-
PTH and calcium x phosphorus levels in hemodialysis patients apy that can control PTH levels without raising serum
with secondary hyperparathyroidism. calcium or phosphorus levels in patients with secondary
hyperparathyroidism.
AMG 073 represents a new class of compounds known
Key words: calcimimetic, calcium-sensing receptor, parathyroid hor-
as calcimimetics. These small molecules act on the para-mone, calcium x phosphorus, secondary hyperparathyroidism, end-
stage renal disease. thyroid gland calcium-sensing receptor, increasing its
sensitivity to extracellular calcium, thereby reducingReceived for publication April 18, 2002
PTH secretion [17, 18]. Calcimimetics have been shownand in revised form July 22, 2002
Accepted for publication August 15, 2002 to inhibit PTH release from parathyroid cells both in
vitro and in vivo and have been proposed as a therapy for 2003 by the International Society of Nephrology
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Fig. 1. Study schema. a, one patient withdrew
consent before receiving study drug; b, three
patients were on a dose of 10 mg at the end
of the maintenance phase.
hyperparathyroidism [19]. These agents reduce plasma care (phosphate binders and/or vitamin D sterols). Pa-
tients were eligible for this study if they met criteria,PTH levels within 1 to 2 hours of oral administration in
humans [20]. The rapid onset of the effects of calcimi- including age 18 years; serum calcium corrected for
serum albumin 8.8 mg/dL and 11.0 mg/dL; serummetic agents suggests that these compounds may permit
precise pharmacological control of PTH secretion in pa- phosphorus 2.5 mg/dL; and calcium x phosphorus
70 (mg/dL)2. Patients receiving vitamin D sterols weretients with secondary hyperparathyroidism.
Single oral doses of AMG 073 have resulted in dose- required to be on a stable dose for at least 21 days before
enrollment. Dialysate calcium concentration and calciumdependent decreases in PTH when administered to he-
modialysis patients with secondary hyperparathyroid- supplements/oral phosphate binders dose could not be
changed during the 7 days before enrollment. Patientsism, while daily doses of 50 mg over 8 days reduced PTH
by 39% [20]. Importantly, decreases in serum calcium, were required to be medically stable with no evidence
of an active infection, malignant process, or diseasephosphorus, and the calcium x phosphorus product were
also observed in this study. In the present 18-week study, known to cause hypercalcemia. Patients were also re-
quired to have a hemoglobin 9.0 g/dL or a hematocritthe efficacy and safety of AMG 073 were assessed in
reducing PTH without concomitant increases in cal- 27%, as well as liver transaminases and bilirubin levels
no more than twice the upper limit of normal.cium x phosphorus in hemodialysis patients with second-
ary hyperparathyroidism.
Study design
This was a placebo-controlled, double-blind, random-
METHODS
ized, multicenter study consisting of two phases: a 12-week
Patients dose-titration phase, followed by a maintenance phase
in which the final dose from the end of the dose-titrationThis study was approved by each study center’s Institu-
tional Review Board or ethics committee and all patients phase was maintained for 6 weeks (Fig. 1).
Patients were randomized 1:1 to receive AMG 073 orgave written informed consent before participation. The
study was conducted at 23 centers in the United States placebo. Patients began on a once daily dose of 20 mg
which could then be titrated up to 30, 40, or 50 mg, orand two in Canada. These centers enrolled 78 patients
treated for at least 3 months with hemodialysis who had down to 10 mg, every 3 weeks until they had achieved
a reduction in PTH values of 30% from baseline andPTH levels 300 pg/mL despite receiving standard of
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Table 1. Baseline characteristics of study patientsto 250 pg/mL, unless the patient had symptoms of
hypocalcemia or the serum calcium was 7.8 mg/dL. Placebo AMG 073 Total
N  39 N  39 N  78The dose of study drug was reduced if patients experi-
Gender number (%)enced PTH values 100 pg/mL on two consecutive
Women 17 (44) 15 (38) 32 (41)weekly visits. Men 22 (56) 24 (62) 46 (59)
Laboratory assessments were made at weekly visits Race number (%)
Black 29 (74) 26 (67) 55 (71)throughout the study to determine the effect of AMG
White 6 (15) 10 (26) 16 (21)073 on PTH, serum calcium, serum phosphorus, and Asian 2 (5) 2 (5) 4 (5)
Hispanic 2 (5) 1 (3) 3 (4)calcium x phosphorus. These assessments were made
Age yearsimmediately before administering the daily oral dose of
Mean (SD) 48.8 (15.6) 52.7 (16.4) 50.8 (16.0)
study medication (24 hours after the dose on the preced- Duration of dialysis months
Number 39 38 77ing day).
Mean (SD) 69.7 (53.9) 60.3 (58.3) 65.1 (55.9)Efficacy was assessed by determining the proportion Range 5–277 3–241 3–277
of patients with reductions in PTH30% between treat- Vitamin D use number (%) 24 (62) 26 (67) 50 (64)
Phosphate binder use number (%) 34 (87) 34 (87) 68 (87)ment groups during the maintenance phase. The mean
percent change from baseline for PTH, serum calcium,
phosphorus, and calcium x phosphorus were also com-
pared between treatment groups during the maintenance
Statistical analysisphase. Safety was assessed by monitoring adverse events,
All patients randomized into the study were includedlaboratory variables (hematology and biochemistry), and
in determining the proportion of patients with reductionsvital signs.
in PTH 30% (drop outs before the maintenance phase
Concomitant medication were considered not to have achieved this reduction).
The mean percent change from baseline through theIn addition to AMG 073 or placebo, patients continued
maintenance phase was determined for PTH, serum cal-to receive their prescribed therapy for secondary hyper-
cium, phosphorus, and calcium x phosphorus. All pa-parathyroidism (phosphate binders and vitamin D ste-
tients who received at least one dose of AMG 073 orrols) during the study. The study protocol provided guid-
placebo were included in the analysis of safety.ance on the use of vitamin D sterols. Reductions in
The proportion of patients with reductions in PTHvitamin D dose were allowed if serum calcium was
30% between treatment groups was compared using
11.0 mg/dL, phosphorus was 6.5 mg/dL, calcium x
the two-group 2 test. The mean percent change fromphosphorus product was 70 (mg/dL)2, or if PTH was
baseline for PTH, serum calcium, phosphorus, and cal-
100 pg/mL on the lowest dose of study drug. Increases
cium x phosphorus were compared between treatment
in vitamin D dose were allowed if PTH was 50% of
groups using an analysis of variance (ANOVA) model.
baseline and the PTH was600 pg/mL. Phosphate bind- Stepwise logistic regression analysis was used to assess
ers could be adjusted as needed throughout the study. the effect of the baseline demographic factors, gender,
age, race, duration of dialysis, and vitamin D use onBiochemical determinations
PTH reductions. This method was also used to assess
All laboratory determinations were conducted at a the effect of baseline PTH, serum calcium, phosphorus,
central laboratory (Covance Laboratory Services, Inc., and calcium x phosphorus levels on PTH reductions.
Indianapolis, IN, USA). Chemistries included alanine Baseline demographic and biochemical data is presented
aminotransferase, aspartate aminotransferase, alkaline as the mean  the standard deviation. Other data are
phosphatase, bone alkaline phosphatase, blood urea ni- presented as the mean  the standard error.
trogen, bilirubin, uric acid, calcium, creatinine, glucose,
cholesterol, triglycerides, sodium, phosphorus, potas-
RESULTSsium, choloride, bicarbonate, total protein and lactate
Patient demographics and dispositiondehydrogenase. These assessments were performed us-
ing standard methodology. PTH levels were determined The baseline patient demographic characteristics were
using a double-antibody immunoradiometric assay for similar between treatment groups (Table 1). The range
the intact hormone (Nichols Institute Diagnostics, San in duration of dialysis among all patients varied from 3
Juan Capistrano, CA, USA). Serum calcium values were to 277 months.
adjusted for the albumin concentration as follows. For Subject disposition at baseline and at the end of the
each 1.0 g/dL decrease in albumin below 4.0 g/dL, the maintenance phase are shown on the study schema (Fig. 1).
Six subjects receiving AMG 073 and five receiving pla-serum calcium was increased by 0.8 mg/dL.
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Table 2. Baseline biochemistry of study patients
Placebo AMG 073
N  39 N  38
iPTH pg/mL
Mean (SD) 637 (455.9) 632 (280.1)
Range 67, 2254 165, 1377
Serum calcium mg/dL
Mean (SD) 9.7 (0.64) 9.7 (0.67)
Range 8.5, 10.8 8.4, 11.1
Serum phosphorus mg/dL
Mean (SD) 5.6 (1.38) 6.3 (1.42)
Range 2.5, 8.7 3.5, 10.7
Ca x P mg/dL2
Mean (SD) 53.8 (13.63) 60.7 (13.21)
Range 21.8, 92.5 30.5, 92.7
Fig. 3. Mean percent change in serum calcium from baseline levels.
Patients received AMG 073 () or placebo (). Values are means 
SE. *P  0.001.
PTH decreased by 24.0% and 29.9% in patients on vita-
min D or not on vitamin D, respectively. In placebo
patients, PTH increased by 19.1% and 27.4% in patients
on or not on vitamin D, respectively.
Stepwise logistic regression analysis indicated that the
baseline demographic factors, gender, age, race, duration
of dialysis, and vitamin D use were not significantly cor-
related with reduction in PTH in patients receiving AMG
073. Baseline PTH, serum calcium, phosphorus, and cal-
cium x phosphorus levels were also not significantly cor-
related with reductions in PTH. Mean percent change
Fig. 2. Mean percent change in PTH from baseline levels. Patients in serum calcium was not significantly correlated with
received AMG 073 () or placebo (). Values are means  SE. *P 
mean percent change in PTH. However, a positive corre-0.001.
lation between the mean percent change in phosphorus
and calcium x phosphorus with the mean percent change
in PTH levels was observed (r  0.341, P  0.057; r 
cebo were discontinued before week 18. Doses of AMG 0.304, P  0.091, respectively).
073 or placebo at the end of the maintenance phase are A significantly greater proportion of patients (38%)
also shown in Figure 1. in the AMG 073-treated group had a 30% decrease in
mean PTH from baseline over the maintenance phase
PTH results compared with the placebo group (8%) (P  0.001).
The baseline PTH levels were similar between treat- Also, a decrease in mean PTH 30% from baseline for
ment groups (Table 2). Figure 2 illustrates the percentage at least one time point during the study occurred in 90%
change from baseline in PTH at each time point for of patients administered AMG 073.
both treatment groups. The mean PTH level over the
Calcium, phosphorus, and calcium x phosphorus resultsmaintenance phase decreased by an average of 26% be-
low baseline levels in patients receiving AMG 073 while The mean baseline serum calcium level was 9.7 mg/dL
it increased by an average of 22% in patients receiving in patients administered both AMG 073 and placebo
placebo (P  0.001). The mean PTH over the mainte- (SD of  0.67 and  0.64, respectively). Figure 3 illus-
nance phase was 460  47.4 pg/mL in patients adminis- trates the percentage change from baseline in serum
tered AMG 073 and 701 70.3 pg/mL in placebo treated calcium at each time point for both treatment groups.
patients. The mean serum calcium level over the maintenance
AMG 073 reduced PTH regardless of baseline vitamin phase decreased by 4.7% in the patients receiving AMG
D use. Sixty-seven percent of the AMG 073-treated sub- 073 compared with no change in the placebo group (P
jects received vitamin D sterols at baseline, compared 0.001).
The mean baseline serum phosphorus was 6.3  1.42with 62% of the placebo patients. In AMG 073 patients,
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Fig. 4. Mean percent change in phosphorus from baseline levels. Pa- Fig. 5. Mean percent change in calcium x phosphorus (Ca x P) from
baseline levels. Patients received AMG 073 () or placebo (). Valuestients received AMG 073 () or placebo (). Values are means  SE.
*P  0.001. are means  SE. *P  0.001.
mg/dL and 5.6  1.38 mg/dL in patients administered
AMG 073 and placebo, respectively. As shown in Fig-
ure 4, patients receiving AMG 073 experienced a 7.5%
reduction in mean serum phosphorus over the mainte-
nance phase, compared with a 10.9% increase in the
placebo patients (P  0.003).
The mean baseline calcium x phosphorus was 60.7 
13.21 (mg/dL)2 and 53.8  13.63 (mg/dL)2 in patients
administered AMG 073 and placebo, respectively. Fig-
ure 5 presents calcium x phosphorus product levels that
decreased by 11.9% over the maintenance phase in pa-
tients administered AMG 073 compared with an increase
of 10.9% in patients receiving placebo (P  0.001).
The effect of AMG 073, compared with placebo, in Fig. 6. Concurrent mean percent change from baseline in PTH ()
and calcium x phosphorus product () during the maintenance phase.reducing both PTH and calcium x phosphorus is pre-
Values are means  SE.sented in Figure 6.
Concomitant therapy
Calcitriol and paricalcitol were the predominant vita- (21% AMG 073, 31% placebo) and dyspnea (18% AMG
min D sterols that patients received during this study. 073, 13% placebo). Transient, asymptomatic hypocal-
The mean weekly dose of calcitriol, the most frequently cemia occurred in 3/38 subjects treated with AMG 073
administered vitamin D therapy, was similar for both (serum calcium 7.5 mg/dL). No clinically meaningful
treatment groups (Fig. 7). The mean weekly dose of changes in laboratory values, vital signs or electrocardio-
paricalcitol was also similar for both treatment groups. grams were evident.
Usage of either calcium-containing or noncalcium-
containing phosphate binders was similar between treat-
DISCUSSIONment groups.
This 18-week dose-titration study demonstrated that
Safety results AMG 073 doses up to 50 mg/day are effective in reducing
AMG 073 was safe and well-tolerated when titrated PTH and calcium x phosphorus levels in hemodialysis
up to a maximum dose of 50 mg/day in this study. The patients with secondary hyperparathyroidism. PTH de-
safety profile of AMG 073 was similar to that of placebo creased by 26% below baseline levels in patients receiv-
with respect to the incidence and severity of adverse ing AMG 073 compared with an increase of 22% in
events. Most adverse events were mild to moderate in patients receiving placebo.
The ability of AMG 073 to reduce PTH was indepen-severity. The most frequent of these events were nausea
Lindberg et al: Calcimimetic reduces parathyroid hormone 253
the PTH reduction was similar for subjects on or not on
vitamin D at baseline (24.0% vs. 29.9%, respectively)
and the effect of AMG 073 on PTH reductions was not
significantly correlated with baseline vitamin D use. In
addition, vitamin D usage was similar between treatment
groups throughout the study, indicating that the PTH
changes were not the result of modulating this concomi-
tant therapy.
In AMG 073-treated patients, reductions in PTH oc-
curred in conjunction with reductions in serum calcium,
phosphorus, and calcium x phosphorus. Serum calcium
and phosphorus decreased significantly in the AMG 073-
treated group relative to patients administered placebo
while calcium x phosphorus levels decreased by 11.9% in
patients administered AMG 073. A therapy that reduces
PTH while also reducing serum calcium, phosphorus,Fig. 7. Mean weekly intervenous (IV) calcitriol dose. Patients received
and calcium x phosphorus represents a significant ad-AMG 073 () or placebo (). At baseline, 16 patients received AMG
073 and 15 received placebo. Values are means  SE vance for ESRD patients. Hyperphosphatemia and ele-
vated calcium x phosphorus are prevalent in this popula-
tion [6, 16, 22, 23]; 50% of ESRD patients have serum
phosphorus levels greater than 6.0 mg/dL and 40% havedent of baseline demographic characteristics, including
calcium x phosphorus levels greater than 60 (mg/dL)2.dialysis vintage. Dialysis vintage has been noted to be a
Baseline serum phosphorus and calcium x phosphorus
key determinant in the severity of secondary hyperpara-
for patients in this study were consistent with these re-
thyroidism [21], indicating that the calcimimetic may
ports. Elevated serum phosphorus and calcium x phos-
benefit patients regardless of disease severity. Consistent phorus are related to the risk of coronary artery disease
with this, patients administered AMG 073 experienced and sudden death in ESRD patients, particularly in the
reductions in PTH independent of baseline PTH levels. setting of elevated PTH levels [22, 23]. In addition, recent
Previous research in hemodialysis patients adminis- work using electron-beam computed tomography has
tered AMG 073 has shown that, while PTH levels remain shown an association between elevated calcium x phos-
below baseline levels for more than 24 hours after admin- phorus and coronary artery calcification in ESRD pa-
istration of single doses of AMG 073, the greatest de- tients [24].
crease in PTH occurs 2 to 4 hours after AMG 073 admin- The reductions in serum calcium and phosphorus in
istration [20]. As the effect of AMG 073 on PTH levels patients administered AMG 073 observed in this study
in the current study was assessed 24 hours after the are similar to those in patients following parathyroidec-
previous dose, the reductions observed here may under- tomy. One explanation for these reductions is a decrease
estimate the full benefit of this therapy on 24-hour PTH in mineral efflux from the bone caused by a reduction
control. in plasma PTH levels. As PTH may indirectly stimulate
Patients enrolled in this study received standard ther- RANKL-mediated osteoclast maturation and activity
apy, including phosphate binders and vitamin D sterols, [25], reductions in PTH could diminish bone resorption.
yet had inadequate control of their secondary hyperpara- Positive correlations were observed between changes in
thyroidism at the start of the study. Mean baseline PTH phosphorus and calcium x phosphorus with changes in
levels were approximately 635 pg/mL in both treatment PTH over the maintenance phase of the study. Phosphate
groups, indicating the severity of the disease in these binder and vitamin D sterol doses were stable in this
patients and the difficulty in controlling it before study study and therefore do not appear to be responsible for
enrollment. Nonetheless, AMG 073 was effective in sig- the reductions in serum calcium and phosphorus levels.
nificantly reducing PTH levels in these subjects. Previous As an extracellular calcium-sensing receptor appears to
studies of second-generation vitamin D sterols have also be expressed in human osteoblasts [26], an alternative
demonstrated reductions in PTH levels [11]. However, hypothesis to explain the observed reductions in serum
these reductions were achieved in patients where base- calcium and phosphorus levels proposes that the mineral
line PTH levels were elevated after withdrawal of calcit- flux between bone and plasma may be influenced by
riol therapy at least 4 weeks before the start of the study. calcimimetic agents.
In the current study, PTH was significantly reduced In summary, the calcimimetic agent AMG 073 may
in the AMG 073 group relative to the placebo group re- offer an advantage over current therapies for the treat-
ment of secondary hyperparathyroidism. As a result ofgardless of baseline vitamin D usage. The magnitude of
Lindberg et al: Calcimimetic reduces parathyroid hormone254
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